Buy Eris Lifesciences; target of Rs 870: Motilal Oswal

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Motilal Oswal's research report on Eris Lifesciences

ERIS delivered an operationally inline 4QFY22. It ended the second consecutive year with earnings growth in the a healthy teens compared to stable earnings over FY18-20. The acquisition of Oaknet Healthcare (Oaknet) enables ERIS to add a Dermatology franchise, expand into the Cosmetology space, and improve synergy in the Women's Healthcare segment. -

Outlook

We tweaked our FY23/FY24 EPS estimate by (3%)/2% to factor in: a) addition of the Oaknet business, b) scale-up in already launched products (Drolute, Xsulin, Zomelis, Gluxit) , c) strong pace of launches over the next 12-15 months, and d) upcoming promotional expenses. We continue to value ERIS at 22x 12-month forward earnings to arrive at a TP of INR870.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More